GANX Earnings — Gain Therapeutics, Inc. Common Stock Post-ER Performance | BigEarnings
GANX — Gain Therapeutics, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$1.95
Market Cap$83.2M
P/E—
52W Range$1.41 – $4.34
Next Earnings2026-08-11
About Gain Therapeutics, Inc. Common Stock
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
